Neximmune announces preliminary phase 1/2 nexi-002 results in patients with multiple myeloma

Gaithersburg, md., dec. 12, 2021 (globe newswire) -- neximmune, inc. (nasdaq: nexi), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific t cells, today announced preliminary phase 1/2 results from an ongoing study of nexi-002, a patient-derived multi-antigen-specific cd8+ t cell treatment for patients with relapsed/refractory multiple myeloma who have failed ≥3 prior lines of therapy. the data on low doses of nexi-002, presented at the 63rd american society of hematology (ash) annual meeting and exposition, showed a promising safety and tolerability profile and evidence of immunologic and clinical activity.
NEXI Ratings Summary
NEXI Quant Ranking